These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 12517802)
61. Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. Beltrami E; Plescia J; Wilkinson JC; Duckett CS; Altieri DC J Biol Chem; 2004 Jan; 279(3):2077-84. PubMed ID: 14581472 [TBL] [Abstract][Full Text] [Related]
62. Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy. Fisker N; Westergaard M; Hansen HF; Hansen JB Nucleosides Nucleotides Nucleic Acids; 2007; 26(10-12):1427-30. PubMed ID: 18066798 [TBL] [Abstract][Full Text] [Related]
63. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. Pennati M; Binda M; Colella G; Folini M; Citti L; Villa R; Daidone MG; Zaffaroni N J Invest Dermatol; 2003 Apr; 120(4):648-54. PubMed ID: 12648230 [TBL] [Abstract][Full Text] [Related]
64. The anti-apoptosis protein, survivin, mediates gastric epithelial cell cytoprotection against ethanol-induced injury via activation of the p34(cdc2) cyclin-dependent kinase. Jones MK; Padilla OR; Webb NA; Norng M J Cell Physiol; 2008 Jun; 215(3):750-64. PubMed ID: 18181150 [TBL] [Abstract][Full Text] [Related]
67. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Zaffaroni N; Daidone MG Drug Resist Updat; 2002 Apr; 5(2):65-72. PubMed ID: 12135582 [TBL] [Abstract][Full Text] [Related]
68. Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysis. Connell CM; Wheatley SP; McNeish IA Cancer Res; 2008 Oct; 68(19):7923-31. PubMed ID: 18829549 [TBL] [Abstract][Full Text] [Related]
69. Participation of Survivin in mitotic and apoptotic activities of normal and tumor-derived cells. Jiang X; Wilford C; Duensing S; Munger K; Jones G; Jones D J Cell Biochem; 2001 Aug 1-9; 83(2):342-54. PubMed ID: 11573250 [TBL] [Abstract][Full Text] [Related]
70. Inhibition of melanoma tumor growth in vivo by survivin targeting. Grossman D; Kim PJ; Schechner JS; Altieri DC Proc Natl Acad Sci U S A; 2001 Jan; 98(2):635-40. PubMed ID: 11149963 [TBL] [Abstract][Full Text] [Related]
71. Targeting survivin in cancer therapy. Pennati M; Folini M; Zaffaroni N Expert Opin Ther Targets; 2008 Apr; 12(4):463-76. PubMed ID: 18348682 [TBL] [Abstract][Full Text] [Related]
72. Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist. Yan H; Thomas J; Liu T; Raj D; London N; Tandeski T; Leachman SA; Lee RM; Grossman D Oncogene; 2006 Nov; 25(52):6968-74. PubMed ID: 16702945 [TBL] [Abstract][Full Text] [Related]
73. Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. Sah NK; Munshi A; Hobbs M; Carter BZ; Andreeff M; Meyn RE Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):852-9. PubMed ID: 17011457 [TBL] [Abstract][Full Text] [Related]
74. Survivin and escaping in therapy-induced cellular senescence. Wang Q; Wu PC; Roberson RS; Luk BV; Ivanova I; Chu E; Wu DY Int J Cancer; 2011 Apr; 128(7):1546-58. PubMed ID: 20503268 [TBL] [Abstract][Full Text] [Related]
75. [Survivin mutants reverse the malignancy of HeLa cells]. Zhu HX; Zhou CQ; Zhang G; Zhou XB; Liu S; Bai JF; Quan LP; Dong ZW; Xu NZ Ai Zheng; 2003 May; 22(5):467-70. PubMed ID: 12753704 [TBL] [Abstract][Full Text] [Related]
76. Phosphorylation of survivin at threonine 34 inhibits its mitotic function and enhances its cytoprotective activity. Barrett RM; Osborne TP; Wheatley SP Cell Cycle; 2009 Jan; 8(2):278-83. PubMed ID: 19158485 [TBL] [Abstract][Full Text] [Related]
77. GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. Shi X; Wang D; Ding K; Lu Z; Jin Y; Zhang J; Pan J Cancer Biol Ther; 2010 Apr; 9(8):640-50. PubMed ID: 20160501 [TBL] [Abstract][Full Text] [Related]
78. Targeting MET transcription as a therapeutic strategy in multiple myeloma. Phillip CJ; Stellrecht CM; Nimmanapalli R; Gandhi V Cancer Chemother Pharmacol; 2009 Mar; 63(4):587-97. PubMed ID: 18509644 [TBL] [Abstract][Full Text] [Related]
79. Benign tumors from the human nervous system express high levels of survivin and are resistant to spontaneous and radiation-induced apoptosis. Hassounah M; Lach B; Allam A; Al-Khalaf H; Siddiqui Y; Pangue-Cruz N; Al-Omeir A; Al-Ahdal MN; Aboussekhra A J Neurooncol; 2005 May; 72(3):203-8. PubMed ID: 15937641 [TBL] [Abstract][Full Text] [Related]
80. Role reversal for anticancer agents. Pardee AB Cancer Biol Ther; 2002; 1(4):426-7. PubMed ID: 12432260 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]